2008•PubMedRequires access

Abacavir/3TC vs. tenofovir/FTC: interim results from ACTG 5202.

Helmut Albrecht

Abstract

On February 28, 2008, the National Institute of Allergy and Infectious Diseases (NIAID) reported that the protocol for ACTG 5202 is being modified because of reduced virologic response in a subset of patients who were receiving abacavir/3TC. This highly anticipated, phase III, multicenter trial involves 1858 HIV-infected adults in the U.S. who were randomized to begin antiretroviral therapy with one of four regimens: The comparison between NRTI backbones is double-blinded, with patients taking a placebo pill for whichever NRTI combination they are not receiving. The comparison between efavirenz …

About this research paper

What this paper is about

Why it matters

OpenAlex reports 5 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Key concepts: Abacavir, Medicine, Efavirenz, Placebo, Antiretroviral therapy, Pill, Internal medicine, Human immunodeficiency virus (HIV)